Results 251 to 260 of about 67,507 (290)

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer. [PDF]

Mol Ther Oncol
Bakos G, Bauder-Wüst U, Landry J, Roscher M, Ramasz B, Bruchertseifer F, Morgenstern A, Kratochwil C, Beneš V, Benešová-Schäfer M.   +9 more
europepmc   +1 more source

RB1 inactivation in cutaneous carcinomas

Histopathology, Volume 88, Issue 4, Page 769-789, March 2026.
Among skin carcinomas, recurrent RB1 inactivation is observed in Merkel cell carcinoma, in a subset of squamous cell carcinoma with bowenoid morphology, in sebaceous carcinoma and in the recently described Wnt/beta‐catenin rosette‐forming carcinoma.
Tiffany Liv, Antoine Touzé, David Schrama, Serge Guyétant, Mahtab Samimi, Michael T Tetzlaff, Benjamin A Wood, Paul W Harms, Thibault Kervarrec   +8 more
wiley   +1 more source

Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet? [PDF]

Curr Oncol
Tao W, Sabel A, Bonfil RD.
europepmc   +1 more source

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Rawat K, Punia V, Mathews P, McCoy S, Song W, Saeed MA, Pachynski RK.   +6 more
europepmc   +1 more source

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer. [PDF]

J Clin Pharmacol
Hadigol M, Williams JH, Shi H, Yang DZ, Hoffman J, Wang DD.   +5 more
europepmc   +1 more source

Emerging Therapeutic Approaches to Engage the Androgen Receptor for the Treatment of Castration-Resistant Prostate Cancer. [PDF]

Cancers (Basel)
Henry I, Foreman R, Balachandran L, Mortimer E, Asim M.   +4 more
europepmc   +1 more source

PFKFB3 as a multifaceted driver and therapeutic target in castration-resistant prostate cancer. [PDF]

Cell Death Dis
Chen L, Xu YX, Ren YY, Wang ZD, Dong XM, Chen YM, Wu P, Wu T, Xiang F, Xie T, Zhang Q, Zhou JL.   +11 more
europepmc   +1 more source

Current status of radionuclide therapies in metastatic castration-resistant prostate cancer. [PDF]

Ther Adv Med Oncol
Fei X, Huang RD, Zhou X, Ye SJ, Nan N, Wang KJ, Ma Q.   +6 more
europepmc   +1 more source

Characterization and validation of a bone metastatic castration-resistant prostate cancer model as a nanomedicine evaluation platform. [PDF]

Theranostics
Serrano-Martí A, Armiñán A, Conejos-Sánchez I, Mittermüller D, Li SW, Lackschewitz PT, Roselló-Sastre E, Gunzer M, Cabral H, Vicent MJ.   +9 more
europepmc   +1 more source